title: The use of latanoprost 0.005% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension.
abstract: OBJECTIVE
  To evaluate the use of latanoprost 0.005% given once daily to simplify a patient's glaucoma medical regimen.
  
  
  METHODS
  We reviewed 527 charts of which we included 61 patients (61 eyes) with either ocular hypertension or primary open-angle glaucoma who were prescribed latanoprost for the purpose of simplifying their glaucoma medical regimen. The successful substitution of latanoprost was defined as a reduction in the number of dosages given daily with the maintenance of intraocular pressure for at least three months no higher than 2 mmHg from the previous medical regimen.
  
  
  RESULTS
  This study showed that 43 of 61 patients (70.4%) had latanoprost substituted allowing for fewer dosages per day. Following the substitution the intraocular pressure in the success group fell from 22.5+/-5.9 mmHg to 18.3+/-3.8 mmHg (p<0.001) over an average follow-up of 6.6+/-1.9 months. The total number of dosages per day in the success group fell from 4.8+/-2.4 to 1.7+/-1.3 at exit (p<0.001). Twenty-two patients had one medicine, 14 patients two, and seven patients three medicines discontinued after latanoprost was added. Reasons for failure after the substitution were ineffectiveness of latanoprost (n=11) or an adverse event (n=7). No trends in the number or types of medicines at baseline discontinued were observed in the success or failure groups.
  
  
  CONCLUSIONS
  This study shows that latanoprost 0.005% once daily can be substituted for one or more medicines in the majority of ocular hypertension and primary open-angle glaucoma patients to simplify the medical regimen.
mesh_terms: D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D009798:Ocular Hypertension / Q000188:drug therapy*; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000627:therapeutic use; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage* / Q000627:therapeutic use; D014792:Visual Acuity